184 related articles for article (PubMed ID: 34435467)
21. Methotrexate level discrepancy post-glucarpidase: A pediatric case series and review of literature.
Kibby D; Trinkman H
Pediatr Blood Cancer; 2024 Mar; 71(3):e30831. PubMed ID: 38149827
[TBL] [Abstract][Full Text] [Related]
22. A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trials.
Janeway KA; Gros L; Schwartz S; Daugherty C; Gallardo E; Hill C; Thomas E; Ward S; Rizzari C
Pediatr Blood Cancer; 2023 Jun; ():e30506. PubMed ID: 37369988
[TBL] [Abstract][Full Text] [Related]
23. [Renal toxicity of high-dose methotrexate].
Garcia H; Leblond V; Goldwasser F; Bouscary D; Raffoux E; Boissel N; Broutin S; Joly D
Nephrol Ther; 2018 Apr; 14 Suppl 1():S103-S113. PubMed ID: 29606256
[TBL] [Abstract][Full Text] [Related]
24. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
25. Production of "biobetter" glucarpidase variants to improve drug detoxification and antibody directed enzyme prodrug therapy for cancer treatment.
AlQahtani AD; Al-Mansoori L; Bashraheel SS; Rashidi FB; Al-Yafei A; Elsinga P; Domling A; Goda SK
Eur J Pharm Sci; 2019 Jan; 127():79-91. PubMed ID: 30343151
[TBL] [Abstract][Full Text] [Related]
26. Glucarpidase treatment for methotrexate intoxication: a case report and review of the literature.
Boelens AD; Mathôt RAA; Vlaar APJ; Bouman CSC
Neth J Med; 2018 Jan; 76(1):36-39. PubMed ID: 29380731
[TBL] [Abstract][Full Text] [Related]
27. Use of glucarpidase (carboxypeptidase-G2) in pediatric cancer patients: 11-year experience of a tertiary center.
Vila R; Rubio-San-Simón A; Zubiaur P; Navares-Gómez M; Gómez-Hernández P; Arce B; Madero L
EJHaem; 2023 Nov; 4(4):1052-1058. PubMed ID: 38024601
[TBL] [Abstract][Full Text] [Related]
28. Glucarpidase Intervention for Delayed Methotrexate Clearance.
Cavone JL; Yang D; Wang A
Ann Pharmacother; 2014 Jul; 48(7):897-907. PubMed ID: 24742398
[TBL] [Abstract][Full Text] [Related]
29. Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients.
Medrano C; Oberic L; Puisset F; Recher C; Larrieu-Ciron D; Ysebaert L; Protin C; Picard M; Perriat S; Chatelut E; Bertoli S; Huguet F; Tavitian S; Faguer S
Leuk Lymphoma; 2021 Apr; 62(4):846-853. PubMed ID: 33179543
[TBL] [Abstract][Full Text] [Related]
30. Glucarpidase for the treatment of life-threatening methotrexate overdose.
Tuffaha HW; Al Omar S
Drugs Today (Barc); 2012 Nov; 48(11):705-11. PubMed ID: 23170306
[TBL] [Abstract][Full Text] [Related]
31. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
32. Intravenous radiographic contrast administered prior to high-dose methotrexate and subsequent toxicity requiring the use of glucarpidase.
Schultz TE; Lynch AC
J Oncol Pharm Pract; 2019 Jun; 25(4):993-997. PubMed ID: 29651915
[TBL] [Abstract][Full Text] [Related]
33. Production of "biobetter" variants of glucarpidase with enhanced enzyme activity.
Al-Qahtani AD; Bashraheel SS; Rashidi FB; O'Connor CD; Romero AR; Domling A; Goda SK
Biomed Pharmacother; 2019 Apr; 112():108725. PubMed ID: 30970523
[TBL] [Abstract][Full Text] [Related]
34. Preventing and Managing Toxicities of High-Dose Methotrexate.
Howard SC; McCormick J; Pui CH; Buddington RK; Harvey RD
Oncologist; 2016 Dec; 21(12):1471-1482. PubMed ID: 27496039
[TBL] [Abstract][Full Text] [Related]
35. Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.
Petersenn S; Hu K; Maldonado M; Zhang Y; Lasher J; Bouillaud E; Wang Y; Mann K; Unger N
Clin Ther; 2012 Mar; 34(3):677-88. PubMed ID: 22364824
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Drug Monitoring of Methotrexate in Plasma Using Ultra High-Performance Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry: Necessary After Administration of Glucarpidase in Methotrexate Intoxications.
Mulder MB; Huisman R; Engels FK; van der Sluis IM; Koch BCP
Ther Drug Monit; 2018 Aug; 40(4):383-385. PubMed ID: 29994985
[TBL] [Abstract][Full Text] [Related]
37. Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.
Ghannoum M; Roberts DM; Goldfarb DS; Heldrup J; Anseeuw K; Galvao TF; Nolin TD; Hoffman RS; Lavergne V; Meyers P; Gosselin S; Botnaru T; Mardini K; Wood DM;
Clin J Am Soc Nephrol; 2022 Apr; 17(4):602-622. PubMed ID: 35236714
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
[TBL] [Abstract][Full Text] [Related]
39. Early intervention is important when administering glucarpidase for methotrexate intoxication. Author's reply.
Miceli G; Daidone M; Corpora F; Di Gaudio F; Tuttolomondo A;
Eur J Intern Med; 2024 Jun; 124():152-153. PubMed ID: 38685140
[No Abstract] [Full Text] [Related]
40. Pharmacokinetic Properties and Tolerability of Cycloserine Following Oral Administration in Healthy Chinese Volunteers: A Randomized, Open-Label, Single- and Multiple-Dose 3-Way Crossover Study.
Zhou H; Wu G; Hu X; Zhu M; Zhai Y; Liu J; Shentu J; Wu L
Clin Ther; 2015 Jun; 37(6):1292-300. PubMed ID: 25869627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
